Compare TSHA & HYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSHA | HYT |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | TSHA | HYT |
|---|---|---|
| Price | $4.67 | $8.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $10.56 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 443.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $8.18 |
| 52 Week High | $6.02 | $9.91 |
| Indicator | TSHA | HYT |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 49.05 |
| Support Level | $4.45 | $8.83 |
| Resistance Level | $4.80 | $8.98 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 60.61 | 57.84 |
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income and capital appreciation. The trust's secondary investment objective is to provide shareholders with capital appreciation. It seeks to achieve its objectives by investing in a diversified portfolio of fixed-income securities.